Investigational Device Exemption (IDE) Trials: Burden or Asset?

Are Investigational Device Exemption (IDE) trials a burden or asset?

Truth is, they can be either, depending on how they're designed.

Ask most device teams about IDE trials, and you'll hear about burdensome protocols, laborious monitoring visits, and budget lines that keep creeping. All fair points, and commonly experienced. But done right, the resulting dataset helps de-risk a device as it heads toward commercialization, which in turn increases its value to potential investors and/or buyers.

When designing an Investigational Device Exemption (IDE) study, you must balance scientific rigor with regulatory compliance and commercial reality. Keep these critical factors in mind as you build your clinical protocol:

• Define clear endpoints: Select specific, measurable primary safety and effectiveness goals that directly support your future marketing claims.
• Lock the device design: Finalize the device design before enrollment — changes mid-trial require costly, time-consuming FDA supplements.
• Calculate statistical power: Work with a biostatistician early to land on a robust sample size that proves clinical significance.
• Build in independent oversight: Establish a Data Monitoring Committee (DMC) and Clinical Events Committee (CEC) to judge adverse events neutrally.
• Standardize investigator training: Create strict training protocols for clinicians to reduce performance variability across different hospital sites.
• Minimize bias: Incorporate blinding or randomization wherever possible, even if a true double-blind setup is out of reach.
• Plan a feasibility stage: Consider a small, early feasibility study (EFS) to test the waters before launching a massive pivotal trial.

So…burden or asset? Mostly a design question, not a fate set in stone.

Thinking about performing an IDE for your device? Reach out and let's think it through together.

M. Alexander Shaw
CEO